Intravenous Lignocaine as an Analgesic Adjunct in Adolescent Idiopathic Scoliosis Surgery (IGNITE-AIS)

June 15, 2021 updated by: University of Malaya

Intravenous Lignocaine as an Analgesic Adjunct in Adolescent Idiopathic Scoliosis Surgery (IGNITE-AIS Study)

This is a single-center study comparing the effect of intravenous (IV) Lignocaine given throughout posterior spinal fusion surgery on the reduction of morphine usage during postoperative period in adolescent idiopathic scoliosis (AIS) patients.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

Study Rationale

Posterior spinal fusion (PSF) performed for the correction of adolescent idiopathic scoliosis (AIS) is a complex surgery which result in severe postoperative pain. Early and adequate analgesia facilitates early mobilization hence reduces postoperative complications. Multimodal analgesia technique has been shown to improve perioperative pain management and significantly reduced the opioid usage and its side effects. Intravenous lignocaine infusion has been used as an analgesic adjunct for the management of acute postoperative pain in many clinical settings which include adult complex spinal surgery. However, until this date no study which examines AIS patients undergoing PSF surgeries.

Study Design

This is a prospective, double-blinded, randomized placebo-controlled trial. Participants will be randomized using a sequentially numbered, opaque sealed envelope (SNOSE) method into two groups: Group A, Lignocaine and Group B, placebo. Group A will receive 1.5mg/kg IV lignocaine bolus prior to induction followed by 2mg/kg/hour of lignocaine infusion throughout surgery until wound closure in which the infusion rate will be halved to 1mg/kg/hour until the end of surgery. The same rate will be infused in the recovery room for another half an hour before patient discharge. Group B will receive saline of similar volume and rate as for Group A.

Study Intervention

The trial drugs are prepared in a 10-ml syringe for the bolus injection and an 50-ml syringe for continuous infusion. For the bolus injection, IV lignocaine 1% will be drawn into the 10-ml syringe according to the weight of the patient (0.15ml/kg) or an equal amount of 0.9% saline. The 50-ml syringe will contained either 50ml of lignocaine 1% solution or 0.9% normal saline solution. Both syringes will be labeled as Drug X.

The depth of anesthesia will be monitored using a processed electroencephalogram (EEG) monitor called Conox (commercial brand name of Fresenius Kabi, Germany depth of anesthesia monitor). There are two indices, the qCON which is the index of hypnotic effect and the qNOX which is the index of pain/nociception. A qCON value of 40-60 indicates general anesthesia state and a qNOX value of 40-60 implies that patient is unlikely to respond to noxious stimuli.

Continuous monitoring of patients will be carried out using invasive blood pressure via radial artery cannulation, heart rate, pulse oximetry and 3-lead electrocardiogram. All participants will be operated utilizing a dual attending surgeon strategy involving two senior surgeons. Intraoperative neurophysiological monitoring using somatosensory and motor evoked potentials will be used throughout the surgery.

All patients will be adequately fasted for at least 6 hours prior to surgery without premedication. The trial drug will be administered to the participants according to the allocation. The bolus injection will be administered over 3 minutes prior to induction followed by an infusion as per protocol. Induction of anesthesia will be performed with IV Target Controlled Infusion (TCI) of Propofol 4-6mcg/ml and TCI Remifentanil 3-5ng/ml. After tracheal intubation, patients will be ventilated with 50% Oxygen/air mixture and anesthesia is maintained with TCI Propofol 2-4mcg/ml and TCI Remifentanil 2-5ng/ml. A qCON value of 40-60 will be targeted intraoperatively. IV Dexamethasone 4mg and IV Morphine 0.5mg/kg will be administered prior to skin incision.

During the maintenance phase of anesthesia if the qCON value is outside this range for longer than 10 seconds, the concentration of Propofol will be increased or decreased by 0.5mcg/ml. After the new target concentration is reached, an additional 20 seconds will be given to bring the qCON value within the pre-established range before making further adjustments.

Upon wound closure, additional IV Morphine 0.5mg/kg will be administered with IV acetaminophen 15mg/kg and IV Ondansetron 0.15mg/kg. IV Fentanyl 0.5mcg/kg will be given prior to cessation of TCI Remifentanil at skin closure. TCI Propofol will be ceased once skin closure is completed. Participants are extubated in the operation room after completion of surgery and transfer to recovery bay for monitoring. The time of discontinuation of TCI Propofol (T0) and the time elapsed from T0 to extubation will be recorded. The qCON value at extubation will be recorded.

The trial drug is continued up to 30 minutes post-operation in the recovery room. Sedation score will be assessed using Richmond Analgesia Sedation Scale (RASS) at the interval of 15 minutes. Pain score will be evaluated using Numerical Rating Scale (NRS) at the interval of 10 minutes. Rescue bolus of IV Fentanyl 10mcg will be given every 5 minutes to treat breakthrough pain when pain score is >=4. Once the pain score is <4, Patient Controlled Analgesia (PCA) with morphine will be started at a concentration of 2mg/ml, a demand dose of 1mg/ml with a lockout interval of 5 minutes and a maximum dose of 20mg over 4 hours without background infusion.

Postoperative analgesia will be maintained using multimodal strategy. Participants will be continued on PCA morphine for up to 48 hours. Participants will receive IV acetaminophen 15mg/kg every 6 hours for the first 24 hour and changed to oral thereafter and oral Celebrex 200mg daily (for <35kg) or 200mg every 12 hours (for >= 35kg), NRS will be recorded every 4 hours until the patient is discharged.

Measurement of Plasma Concentration Levels of Lignocaine

5mls of blood samples will be collected from participants using Ethylenediaminetetraacetic acid (EDTA) tube 30 minutes, 2 hours, 4 hours and 8 hours after the bolus injection. Collected blood samples will be centrifuged immediately and the plasma will be transferred into cryo vials in duplicates and kept at -80 degree Celsius until further analysis.

To extract lignocaine from plasma 0.5ml volume of plasma, 0.1ml internal standard (IS) solution (500ng/ml), 0.1ml 1Molar of Sodium Hydroxide (NaOH) and 3ml of methyl-tert-butyl ether (MTBE) will be placed in a 4.5ml propylene tube. The content will be mixed for the minimum of 5 minutes by the shaker and then centrifuged at 3000-3500rpm for 5 minutes. The top layer will be transferred to a 4.5ml propylene tube containing 0.25ml of 0.1% Formic acid. The tube will be mixed again for the minimum of 5 minutes by the shaker and then centrifuge at 3000-3500rpm for 5 minutes. The top solvent layer will be discarded by vacuum and the remaining solution will be transferred into an autosampler vial. A 100 microliter volume will be injected into the analytical column connected to light chain mass spectrometry system. The calibration curve will be plotted by the ratio of the lignocaine/IS vs the concentration of lignocaine. The concentration of lignocaine in all samples will be calculated from the calibration curve.

Data Analysis

All data will be tabulated in a computer files and analyzed using International Business Machines Statistical Package for the Social Sciences (IBM SPSS) software version 25. All randomized participants will be analyzed according to their original allocation according to the (modified) intention-to-treat principle except those who deemed ineligible after randomization or the treatment is never started (such as last minute cancellation of surgery). Data normality will be assessed by using the Kolmogorov-Smirnov test and confirm with visual inspection of the histogram. Categorical data will be presented as counts and percentage. Continuous date will be expressed as mean +/- standard deviation, or median (Q1-Q3) for data with skewed distribution. Data differences between the two groups will be computed by independent t-test or Mann Whitney U test for continuous data and the Chi square test for categorical data.

The mean plasma concentration of lignocaine will be plotted against time from bolus injection and during continuous infusion perioperatively until the infusion is discontinued.

The primary outcome, postoperative morphine consumption at 24 hour and Propofol requirements between group, will be analyzed by using independent t-test. Mixed analysis of variance (ANOVA) will also be conducted to determine whether the change in the use of PCA morphine over time (at 12 hours, 24 hours, 36 hours and 48 hours post-surgery), the change in target effect site concentration of Propofol and remifentanil and qCON value over time are the result of the interaction between the two groups and time. If an interaction is present, the differences between group at each time point will be calculated and compared by using the independent t-test; however, if no statistical interaction is present, the main effects of the analysis will be reported. The occurrence of adverse events or complications will be compared between group by using the Chi square test. A Kaplan-Meier analysis will be conducted for time-to-first flatus, time-to-first ambulation and time to recovery from anesthesia and will be compared between group using Mantel-Cox test. A 2-sided p<0.05 is considered statistical significant.

Study Type

Interventional

Enrollment (Anticipated)

102

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • Malaysia
    • Kuala Lumpur
      • Pantai Valley, Kuala Lumpur, Malaysia, 59100
        • Recruiting
        • University Malaya
        • Contact:
        • Sub-Investigator:
          • Siti Nadzrah Yunus, Postgraduate

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

10 years to 18 years (Child, Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • American Society of Anaesthesiologists (ASA) physical status I and II

Exclusion Criteria:

  • Hypersensitivity to amide local anaesthetics/lignocaine
  • Liver disease (alanine aminotransferase, ALT or aspartate aminotransferase, AST more than twice normal)
  • Renal impairment (defined as estimated Glomerular Filtration Rate <= 60ml/min)
  • History of cardiac disease/cardiac arrhythmia
  • Epilepsy
  • Intellectual disability
  • Preoperative chronic pain with regular opioid usage

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Lignocaine
This arm will receive intravenous Lignocaine bolus and infusion
Drug: Lignocaine
Group A will receive 1.5mg/kg IV lignocaine bolus prior to induction followed by 2mg/kg/hour of lignocaine infusion throughout surgery until wound closure in which the infusion will be halved to 1mg/kg/hour until the end of surgery. The same rate will be infused in the recovery room for another half an hour before participant is discharge.
Other Names:
  • Group A
Placebo Comparator: Placebo
This arm will receive Normal saline 0.9% bolus and infusion
Drug: Normal saline
Group B will receive saline of similar volume and rate as Group A
Other Names:
  • Group B

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
To evaluate postoperative morphine consumption at 24 hours
Time Frame: Immediately post-operation until 24 hours post-operation
Amount of patient controlled analgesia (PCA) morphine usage in mg over 24 hours
Immediately post-operation until 24 hours post-operation

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
To determine the safe dose of intravenous infusion (IVI) lignocaine by measuring the plasma concentration levels
Time Frame: 30 minutes, 2 hours, 4 hours and 8 hours after the bolus dose of trial drug
Blood sample either arterial (intra-operative) or venous (post-operative) will be collected and the plasma will be evaluated using Light Chain Mass Spectrometry to determine the concentration of lignocaine in the blood at specific time point
30 minutes, 2 hours, 4 hours and 8 hours after the bolus dose of trial drug
To evaluate the effect on propofol dose requirement as measured by processed electroencephalogram (EEG) qCON index
Time Frame: From the start of anaesthesia until the end of surgery (Throughout the surgery which may range from 2 to 5 hours))
Total amount of propofol usage in milligram or the dose of propofol required throughout the surgery to maintain qCON value between 40-60 throughout the surgery will be documented and compared between 2 groups as lignocaine has been shown to have anaesthetic sparing effect. Processed EEG is an automated device of summation of raw EEG that generate dimensionless index value between 0 to 100. It does not specifically focus on single EEG waveform.
From the start of anaesthesia until the end of surgery (Throughout the surgery which may range from 2 to 5 hours))

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
To evaluate the postoperative numeric rating scale (NRS) at rest and during movement
Time Frame: Immediately after the operation until 48 hours after the operation
Charting of numeric rating scale (NRS) at rest and during movement every 10 minutes at recovery room and 4 hourly in the ward will be compared between to 2 groups to evaluate the effectiveness of lignocaine as analgesic adjunct. The scale has a scale of 0 to 10. 0 is equivalent to no pain and scale of 10 is equivalent to severe and worst pain.
Immediately after the operation until 48 hours after the operation
To determine any adverse events or complications following administration of systemic lignocaine until hospital discharge
Time Frame: The adverse event will be observed from the time of administration of study drug until the participants are discharge from hospital after the operation. (through the perioperative period, an average of 4 days)
The incidence of any adverse event that occur including postoperative nausea and vomiting, perioral numbness and seizure, constipation will be recorded for all participants
The adverse event will be observed from the time of administration of study drug until the participants are discharge from hospital after the operation. (through the perioperative period, an average of 4 days)
To determine the effect of intravenous infusion (IVI) Lignocaine on postoperative return of bowel function
Time Frame: The observation will be done by calculating the hours after the surgery (from the start of postoperative time) to the return of passing first flatus as a measure of bowel opening, assessed up to 72 hours, whichever comes first
We are comparing the rate of postoperative delay in returning of bowel habit between this two groups by measuring the time of participant passing first flatus after the surgery
The observation will be done by calculating the hours after the surgery (from the start of postoperative time) to the return of passing first flatus as a measure of bowel opening, assessed up to 72 hours, whichever comes first
To determine the effect of intravenous infusion (IVI) lignocaine on postoperative ambulation
Time Frame: The hours after the surgery (from the start of postoperative time) until the participants have their first ambulation will be calculated, assessed up to 72 hours, whichever comes first
We are comparing the rate of postoperative delay in returning to normal activity specifically mobility in spine surgery as a consequences of inadequate pain control between the 2 groups by measuring the time of first ambulation for all participant
The hours after the surgery (from the start of postoperative time) until the participants have their first ambulation will be calculated, assessed up to 72 hours, whichever comes first
To evaluate the length of hospital stay
Time Frame: The number of days through hospital stay after the surgery (number of postoperative day in hospital), an average of 4 days
To evaluate the impact of lignocaine as analgesic adjunct in the change of the number of days spent in the hospital for recovery after surgery
The number of days through hospital stay after the surgery (number of postoperative day in hospital), an average of 4 days
To evaluate the effect of lignocaine on intraoperative somatosensory evoked potential and motor evoked potential reading
Time Frame: The time starts from beginning of the surgery until the end of surgery (up to 300 minutes)
To evaluate the effect of intravenous infusion (IVI) Lignocaine on the amplitude of both somatosensory and motor evoked potential reading recorded throughout the surgery and to compare the difference with placebo
The time starts from beginning of the surgery until the end of surgery (up to 300 minutes)
To determine the hypnotic effect of lignocaine on recovery time from anaesthesia
Time Frame: The time starts from the discontinuation of TCI Propofol to the time participant is extubated from the endotracheal tube which may vary from 15 to 30 minutes
Comparison will be made between both groups whether there is a delay in recovery from anaesthesia by recording the time taken (in minutes) for each participant to be fully awake and extubated from the endotracheal tube once the TCI Propofol is discontinued.
The time starts from the discontinuation of TCI Propofol to the time participant is extubated from the endotracheal tube which may vary from 15 to 30 minutes
To determine the antinociceptive property of lignocaine as measured by qNOX value
Time Frame: The time starts from beginning of the surgery until the end of surgery (up to 300 minutes)
qNOX value will be blinded throughout the surgery and will be separately recorded. The trend of this value will be compared between 2 groups whether lignocaine has significant effect on to lower the qNOX value
The time starts from beginning of the surgery until the end of surgery (up to 300 minutes)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Malaya

Investigators

  • Principal Investigator: Mohd Shahnaz Hasan, Postgraduate, University Malaya

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 24, 2020

Primary Completion (Anticipated)

March 31, 2022

Study Completion (Anticipated)

September 30, 2022

Study Registration Dates

First Submitted

January 24, 2021

First Submitted That Met QC Criteria

June 15, 2021

First Posted (Actual)

June 18, 2021

Study Record Updates

Last Update Posted (Actual)

June 18, 2021

Last Update Submitted That Met QC Criteria

June 15, 2021

Last Verified

June 1, 2021

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • UM.M/PDR/638/3(151)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Analgesia

Clinical Trials on Lignocaine

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Italy

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe